Transcarent
Unicorn · $2.2B15 known investors
Transcarent operates a generative AI-powered health and care platform that combines medical, pharmacy, and point solutions to help people navigate the healthcare system and access on-demand care. It is sold to employers as a single point of access for their members, aiming to reduce healthcare complexity and cost.
Also known as Transcarent, Inc.
Investors · 15
.png)
Also in the syndicate · 6
Funding
SEC filings, press & company announcements$126M disclosed across 1 round · 2024
- $126MSeries DMay 2024 · 2 sources
7wireVentures (lead), General Catalyst (lead), Ally Bridge Group, Alta Partners, Geodesic Capital, Human Capital, Kinnevik, Leaps by Bayer, Memorial Hermann Health System, Merck Global Health Innovation Fund, Threshold Ventures
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Company profile
researched Aug 2026Transcarent operates a health and care platform sold primarily to self-insured employers and health plans, positioning itself as the "One Place for Health and Care." Its core product, the WayFinding experience, uses what the company calls doctor-informed agentic AI alongside human Health Guides and clinicians to cover three functions: benefits navigation (plan-specific answers about medical, pharmacy and point-solution benefits), clinical guidance (symptom checking, follow-up, and virtual expert medical opinions via 2nd.MD), and care delivery (24/7 chat-based care, same-day video visits with board-certified physicians, virtual mental health therapy, and scheduling of in-person care).
Around the navigation layer, Transcarent offers a set of "Care Experiences" in specific clinical areas, including Pharmacy Care, Weight Health, Surgery Care, Cancer Care, and 2nd.MD expert medical opinions; the company states it offers Care Experiences in seven high-impact clinical areas. Earlier descriptions of the platform also referenced Everyday Care (including "Care in 60 Seconds") and behavioral health. Platform features added in the WayFinding 2.0 release include intelligent scheduling, symptom checking, a Total Recall Memory Engine that retains prior visit and conversation context, and a Personalized Health Path.
The company has grown partly through acquisition and merger: it acquired BridgeHealth, a surgical and value-based care provider, acquired and integrated the 98point6 AI-powered virtual care platform and care business (including the affiliated Transcarent Clinic) in 2023, and subsequently merged with Accolade. Transcarent also maintains an internal AI Governance Committee and published AI Ethics Principles aligned with OECD principles, is a member of the Data & Trust Alliance, signed the Voluntary Healthcare AI Commitments for Generative AI, and has participated in US federal policy forums on healthcare AI.
Business model
Transcarent sells its platform to self-insured employers and health plans, which make it available to employees and members as a single point of access to medical, pharmacy and point-solution benefits plus virtual and in-person care. The company states it is aligned with those who pay for healthcare and takes accountability for results, offering at-risk pricing models and transparent impact reporting. At the time of the Series C, the company described a fully at-risk model that pays providers up front for care and partners with employers without up-front or per-employee-per-month (PEPM) fees, with most Members receiving no bills and not being responsible for co-pays or co-insurance.
Employer- and health-plan-sponsored contracts based on at-risk pricing tied to outcomes and cost impact rather than up-front or per-employee-per-month fees, as described at the time of the Series C round.
Traction
As of the May 2024 Series D announcement, more than 4.3 million people had access to Transcarent through their employer or health plan. The company later reported serving over 20 million lives and partnering with 35 health plans. Cited outcome claims from internal analysis and book-of-business data include a share of benefit inquiries resolved by the AI Care Assistant, reduced avoidable emergency room and urgent care visits, improved treatment plans through expert medical opinions, and average savings per surgical episode.
Latest developments
In January 2026 Transcarent announced WayFinding 2.0, adding scheduling, symptom checking, a Total Recall Memory Engine and a Personalized Health Path to the platform. The company has described its merger with Accolade as enhancing WayFinding's data, technology and care quality, and Transcarent and Accolade jointly market AI-powered guidance to health plans.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Transcarent competes in health benefits navigation and virtual care for employers, a category the company distinguishes itself from by combining navigation, clinical guidance and care delivery in one platform. It reports serving over 20 million lives and $950 million in funding, partnerships with 35 health plans, and recognition on CNBC's Disruptor 50 list in 2024 and 2025 as well as coverage by Forbes and STAT News. Following its Series D it was valued at $2.2 billion.
The company positions WayFinding as a Member-facing AI solution spanning benefits navigation, clinical guidance and care delivery in a single experience, with context carried across interactions by a memory engine and human clinicians available alongside AI. Its commercial model — at-risk pricing without up-front or PEPM fees, paying providers up front, and removing member co-pays and co-insurance in many cases — was described as differentiating versus other navigation and virtual care companies.
Technology
The WayFinding platform combines generative and agentic AI with software, data science, and human clinicians and Health Guides. Capabilities include an AI Care Assistant that answers benefits questions customized to an employer's plan design and networks, symptom checking and urgency triage, AI-powered appointment booking and coordination, and a memory engine that carries context and care history across interactions. The company states its AI supports licensed clinicians rather than replacing or overruling them, and cites HIPAA compliance, SOC 2 certification, adversarial testing, and safeguards for privacy and bias.
Go-to-market
Direct enterprise sales to self-insured employers and health plans, supported by demo requests, webinars and published research and insights content for HR and benefits leaders. Transcarent has also used distribution and ecosystem partnerships, including Walmart selecting Transcarent as its go-to-market solution for self-insured employers, and a National Independent Provider Ecosystem launched with 12 leading health systems.
Self-insured employers and their employees and families, and health plans; Transcarent reports partnerships with 35 health plans. Named client references include Pilot Company.
Geography
United States. The Series C announcement was issued from Palo Alto, California and described the company as Silicon Valley-based; the Series D announcement was issued from San Francisco, California.
History
Transcarent was founded in 2020 and is led by CEO Glen Tullman, the former Livongo CEO and a managing partner at 7wireVentures; Ken Frazier, former Merck chairman and CEO, serves as Executive Chairman. In its first year the company built out its leadership team and acquired BridgeHealth, a provider of surgical and value-based care serving over one million members, and was selected by Walmart as its go-to-market solution for self-insured employers. It raised a $200 million Series C in January 2022, bringing total funding to $298 million. Between 2022 and 2024 it launched Weight Health, Cancer, Behavioral Health and Pharmacy Care Experiences, expanded its value-based Surgery Centers of Excellence program, acquired and integrated the 98point6 AI-powered virtual care platform in 2023, and launched a National Independent Provider Ecosystem with 12 health systems. It introduced the WayFinding AI consumer health experience in May 2024 and raised a $126 million Series D that month at a $2.2 billion valuation. It subsequently merged with Accolade and released WayFinding 2.0 in January 2026.
Risks & controversies
Published outcome and savings figures are drawn from the company's internal analysis, book-of-business data and client results, and the company notes that results vary depending on plan design, population, geography, engagement and participating providers.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 11
launches, deals, and filingsTranscarent states its merger with Accolade enhanced the WayFinding experience with additional data, technology and care capabilities; the two now jointly partner with health plans.
Transcarent was invited to participate in the Senate AI Caucus' Health AI Demo Day on Capitol Hill; the company also signed the Voluntary Healthcare AI Commitments for Generative AI and its Lead Product Manager for AI, Benjamin Nguyen, MD, testified before the House Energy & Commerce Subcommittee on Health.
Series D led by General Catalyst and 7wireVentures, with new investors Geodesic Capital and Memorial Hermann Health System and support from existing investors; proceeds earmarked for AI capabilities, commercial growth and strategic growth opportunities.
$126M source ↗
Transcarent launched a National Independent Provider Ecosystem with 12 leading health systems to deliver a higher-quality, more affordable consumer experience for self-insured employers.
Transcarent completed the acquisition and integration of the 98point6 AI-powered virtual care platform and care business, which includes the affiliated Transcarent Clinic.
Series C led by Kinnevik and Human Capital with participation from Ally Bridge Group and health systems Northwell Health, Intermountain Healthcare and Rush University Medical Center, plus existing investors, bringing total funding to $298 million.
$200M source ↗
Transcarent completed the acquisition and integration of BridgeHealth, a provider of surgical and value-based care serving over one million Members.
Walmart selected Transcarent as its go-to-market solution for self-insured employers, with the companies working together to give self-insured employers and employees access to Walmart services including low-cost pharmaceutical pricing.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
In the news
▸Research sources · 8
primary sources listed
- Transcarenttranscarent.ai · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Transcarent do?
- Health and care platform combining AI-powered navigation, clinical guidance and virtual care for self-insured employers.
- Who are Transcarent's investors?
- Transcarent's investors include Alta Partners, Threshold Ventures, Ally Bridge Group, General Catalyst, Geodesic Capital, Human Capital, Kinnevik, Leaps by Bayer and 1 more.
- How much funding has Transcarent raised?
- Transcarent has disclosed $126M raised across 1 round.